BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

IBI311: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 0 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Innovent Biologics (Suzhou) Co. Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT07113262 A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseThyroid Eye Diseaserecruiting111

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
None in the last 180 days.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.